Marwan Mahtook
Research Subjects
Research Interests
Marwan Mahtook has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Khulood Majid Alsaraf
Al-Esraa University College
1 shared publication - Maiss Saadi1 shared publication
- Noor Mohammed Obaid
College of Pharmacy, Al-Esraa University, Baghdad , Iraq
1 shared publication - Saifan Alhameedawi1 shared publication
Latest Publications
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 141-144
Real-world data on the effectiveness of the meloxicam and pridinol combination for musculoskeletal pain
Musculoskeletal pain includes several types of discomfort associated with the skeletal system. Pharmaceutically, pridinol was developed in order to relax muscles. No empirical data exist to support the effectiveness of using meloxicam in combination therapy for the treatment of musculoskeletal pain. This study compared pridinol and meloxicam for musculoskeletal pain. The current observational study assessed a total of 82 patients. The study’s participants were divided into three groups: the “meloxicam” group, the “pridinol” group, and the “meloxicam + pridinol” group. Pain levels were measured before and four weeks after giving the drug, by using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We employed a Kruskal-Wallis test in order to evaluate the variations in pain measurement among the groups. The three groups’ VAS and WOMAC scores did not differ before the drug administration. The “meloxicam + pridinol” treatment resulted in significant pain relief based on VAS and WOMAC scores at 1, 2, and 4 weeks (as compared to other groups; p<0.05). At 4 weeks, the VAS and WOMAC ratings exhibited no significant pain relief in the “meloxicam” group when compared to the “pridinol” group. The meloxicam-pridinol combination proved efficacious for musculoskeletal pain, and is recom¬mended for its therapy.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 141-144
Real-world data on the effectiveness of the meloxicam and pridinol combination for musculoskeletal pain
Musculoskeletal pain includes several types of discomfort associated with the skeletal system. Pharmaceutically, pridinol was developed in order to relax muscles. No empirical data exist to support the effectiveness of using meloxicam in combination therapy for the treatment of musculoskeletal pain. This study compared pridinol and meloxicam for musculoskeletal pain. The current observational study assessed a total of 82 patients. The study’s participants were divided into three groups: the “meloxicam” group, the “pridinol” group, and the “meloxicam + pridinol” group. Pain levels were measured before and four weeks after giving the drug, by using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We employed a Kruskal-Wallis test in order to evaluate the variations in pain measurement among the groups. The three groups’ VAS and WOMAC scores did not differ before the drug administration. The “meloxicam + pridinol” treatment resulted in significant pain relief based on VAS and WOMAC scores at 1, 2, and 4 weeks (as compared to other groups; p<0.05). At 4 weeks, the VAS and WOMAC ratings exhibited no significant pain relief in the “meloxicam” group when compared to the “pridinol” group. The meloxicam-pridinol combination proved efficacious for musculoskeletal pain, and is recom¬mended for its therapy.